1,4-diazine Ring Patents (Class 544/120)
-
Publication number: 20030191117Abstract: The present invention relates to acyclic piperazine and piperidine derivatives, which are especially useful for treating or preventing neuronal damage, particularly damage associated with neurological diseases. These compounds are also useful for stimulating nerve growth. The invention also provides compositions comprising the compounds of the present invention and methods of utilizing those compositions for treating or preventing neuronal damage or for stimulating nerve growth.Type: ApplicationFiled: June 13, 2002Publication date: October 9, 2003Inventors: David Lauffer, Ronald Tomlinson, Eckhard Ottow, Martyn Botfield
-
Publication number: 20030166653Abstract: This invention relates to a novel form of a serotonin h5-HT1B-receptor antagonist, namely a novel form of a salt of (R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphtyl]-4-morpholinobenzamide referred to as (R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphtyl]-4-morpholinobenzamide monohydrobromide Form A. The invention also relates to processes for preparation of said of Form A, which form has a potential use after suitable pharmaceutical formulation in medical treatment, preferably in CNS disorders, over active bladder or vasospam, or growth control of tumors.Type: ApplicationFiled: January 17, 2003Publication date: September 4, 2003Inventors: Per-Olov Bergstrom, Martin Hedberg, Mona Lindstrom, Erica Stahle
-
Publication number: 20030166630Abstract: The present invention relates to new derivatives of amino acids and their use as medicaments.Type: ApplicationFiled: October 31, 2002Publication date: September 4, 2003Inventors: Serge Auvin, Jeremiah Harnett, Pierre-Etienne Chabrier De Lassauniere
-
Publication number: 20030162967Abstract: The present invention relates to compounds of the formula I, 1Type: ApplicationFiled: August 26, 2002Publication date: August 28, 2003Applicant: Aventis Pharma Deutschland GmbHInventors: Otmar Klingler, Gerhard Zoller, Elisabeth Defossa, Fahad A. Al-Obeidi, Armin Walser, James Ostrem
-
Patent number: 6610677Abstract: This invention describes novel pyrazole compositions comprising a pharmaceutically acceptable carrier and a compound of formula VIII: wherein Z1 is N or C—R9, Z2 is N or CH, and Z3 is N or C—Rx, provided that one of Z1 and Z3 is nitrogen; G is Ring C or Ring D; Ring C is selected from a phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl ring, wherein said Ring C has one or two ortho substituents independently selected from —R1; Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; and Rx, R1, R2, R2′, R3, and R9 are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.Type: GrantFiled: September 14, 2001Date of Patent: August 26, 2003Assignee: Vertex Pharmaceuticals IncorporatedInventors: Robert Davies, Pan Li, Julian M. C. Golec, Jean-Damien Charrier, Ronald Knegtel, David Bebbington
-
Publication number: 20030158210Abstract: The present invention concerns novel compounds of formula 1Type: ApplicationFiled: November 15, 2002Publication date: August 21, 2003Inventors: Lieven Meerpoel, Jan Heeres, Robert Jozef Maria Hendrickx
-
Publication number: 20030144291Abstract: The present invention relates to new piperidyl- or piperazinyl-substituted indan derivatives having the formula I 1Type: ApplicationFiled: January 9, 2003Publication date: July 31, 2003Inventors: Stefan Berg, Lennart Florvall, Svante Ross, Seth-Olov Thorberg
-
Publication number: 20030139409Abstract: A compound which is a benzo[a]phenazine-11-carboxamide derivative of formula (I) wherein each of R1 to R4, which are the same or different, is selected from hydrogen, halogen, hydroxyl, C1-C6 alkoxy which is unsubstituted or substituted, heteroaryloxy, C1-C6 alkyl which is unsubstituted or substituted, nitro, cyano, azido, amidoxime, CO2R10, CON(R12)2, OCON(R12), SR10, SOR11, SO2(R11), SO2N(R12)2, N(R12)2, NR10SO2R11, N(SO2R11)2NR10(CH2)nCN, NR10COR11, OCOR11 or COR10; each of R5 to R7, which are the same or different, is selected from hydrogen, halogen, hydroxy, C1-C6 alkoxy, C1-C6 alkyl, SR10 and N(R12)2; Q is C1-C6 alkylene which is unsubstituted or substituted by (i) C1-C6 alkyl which is unsubstituted or substituted, (ii) hydroxy, provided that the hydroxy group is not, to either of the N atoms adjacent to Q in formula (I), (iii) CO2R10, or (iv) CON(R12); R1 and R9, which are the same or different, are each hydrogen or C1-C6 alkyl, or R8 and R9 together with the nitrogen atom to which they are aType: ApplicationFiled: September 18, 2002Publication date: July 24, 2003Inventors: John Milton, Nigel Vicker, Adrian Folkes, Shouming Wang, William Alexander Denny
-
Publication number: 20030134840Abstract: The invention provides compounds of general formula 1Type: ApplicationFiled: January 9, 2003Publication date: July 17, 2003Applicant: AstraZeneca AB, a Sweden corporationInventors: Andrew Baxter, Stephen Brough, Nicholas Kindon, Thomas Mclnally, Bryan Roberts, Stephen Thom
-
Publication number: 20030119811Abstract: Compounds represented by Formula (I): 1Type: ApplicationFiled: April 2, 2002Publication date: June 26, 2003Inventors: Nigel J. Liverton, John W. Butcher, Charles McIntyre, Christopher F. Claiborne, David A. Claremon, John A. McCauley, Joseph J. Romano, Wayne Thompson, Peter M. Munson
-
Publication number: 20030120070Abstract: The present invention relates to a series of 4-phenylpiperazines of formula (I) 1Type: ApplicationFiled: December 30, 2002Publication date: June 26, 2003Applicant: H. Lundbeck A/SInventors: Jens Kristian Perregaard, Ejner Kund Moltzen
-
Publication number: 20030114668Abstract: This invention relates to piperazine derivatives of formula (I), wherein Y is bond or lower alkylene, R1 is aryl which may have substituent(s), R2 is aryl or indolyl, each of which may have substituent(s), R3 is hydrogen or lower alkyl, and R4 is as defined in the description, and its pharmaceutically acceptable salt, to processes for preparation thereof, to pharmaceutical composition comprising the same, and to a use of the same for treating or preventing Tachykinin-mediated diseases in human beings or animals.Type: ApplicationFiled: January 7, 2000Publication date: June 19, 2003Inventors: HIROSHI MIYAKE, KAZUHIKO TAKE, SHINJI SHIGENAGA, HIDENORI AZAMI, HIROSHI SASAKI, YOSHITERU EIKYU, KAZUO NAKAI, JUNYA ISHIDA, TAKASHI MANABE, NOBUKIYO KONISHI, TADASHI TERASAKA
-
Patent number: 6579982Abstract: The present invention relates to pyrimidine-2,4,6-trione metalloproteinase inhibitors of the formula wherein X, Y, Ar1, Z, R1, R2 and R3 are as defined in the specification, and to pharmaceutical compositions and methods of treating inflammation, cancer and other disorders.Type: GrantFiled: August 9, 2000Date of Patent: June 17, 2003Assignee: Pfizer Inc.Inventor: Julian Blagg
-
Publication number: 20030100548Abstract: 1 Compounds of formula (I) wherein Z is —CH2SR and R represents hydrogen or —COCH3, are useful as metalloproteinase inhibitors, especially as inhibitors of MMP 13.Type: ApplicationFiled: September 20, 2002Publication date: May 29, 2003Inventors: Bernard Christophe Barlaam, Nicholas John Newcombe, Howard Tucker, David Waterson
-
Patent number: 6559155Abstract: Pyrimidones of formula (I) are inhibitors of the enzyme LpPLA2 and thereof use in treating inter alia atherosclerosis, in which: R1 is COOH or a salt thereof, COOR10, CONR11R12, CN or CH2OH; R2 is a mono- or bicyclic aromatic ring system or a mono- or bicyclic heteroaromatic ring system; R3 is C1-20alkyl, C3-6cycloalkyl, C3-6cycloalkylC1-5alkyl, C1-10alkoxyC1-10alkyl, or an aromatic or heteroaromatic ring system; W is SO2 or a bond; X is O or S; and Y is a group of the formula A1—A2—A3 in which A1 and A3 each represent a bond or a straight chain or branched alkylene group, said alkylene group(s) containing a total of 1 to 10 carbon atoms and A2 represents a bond or O, S, SO, SO2, CO, C═CH2, CONH, NHCO, CR15R16, CH═CH or C═C, providing that when A2 is O, S, SO, SO2 or CONH, A3 contains at least two carbon atoms linking the A2 group and the CH2 group in formula (I).Type: GrantFiled: February 21, 2001Date of Patent: May 6, 2003Assignee: SmithKline Beecham p.l.c.Inventors: Colin Andrew Leach, Stephen Allan Smith
-
Publication number: 20030083327Abstract: This invention describes novel pyrazole compositions comprising a pharmaceutically acceptable carrier and a compound of formula VIII: 1Type: ApplicationFiled: September 14, 2001Publication date: May 1, 2003Inventors: Robert Davies, Pan Li
-
Patent number: 6548512Abstract: The present application describes nitrogen containing heteroaromatics and derivatives thereof of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein J is N or NH and D may be C(═NH)NH2, which are useful as inhibitors of factor Xa.Type: GrantFiled: January 27, 2000Date of Patent: April 15, 2003Assignee: Bristol-Myers Squibb Pharma CompanyInventors: Donald Joseph Phillip Pinto, James Russell Pruitt, Joseph Cacciola, John Matthew Fevig, Qi Han, Michael James Orwat, Mimi Lifen Quan, Karen Anita Rossi
-
Publication number: 20030028017Abstract: Disclosed is a novel method of producing heteroaryl amines of the formula(I): 1Type: ApplicationFiled: July 11, 2001Publication date: February 6, 2003Inventors: Nathan Yee, Suresh R. Kapadia, Jinhua J. Song
-
Publication number: 20030013708Abstract: Provided herein is a compound having the formula (I): 1Type: ApplicationFiled: January 16, 2002Publication date: January 16, 2003Inventors: Edward Pierson, Daniel Sohn, Markus Haeberlein, Timothy Davenport, Marc Chapdelaine, Carey Horchler, John P. McCauley
-
Publication number: 20020183316Abstract: Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives of the general formula 1Type: ApplicationFiled: October 22, 2001Publication date: December 5, 2002Inventors: Kevin Pan, Michael H. Parker, Allen B. Reitz, Steven J. Coats, Cheryl P. Kordik, Chi Luo
-
Patent number: 6476016Abstract: Cyclic oxyguanidine pyrazinone compounds are described, including compounds of the Formula I: wherein R3, R4, R5, W, and A are as set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin. Compositions for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation are described.Type: GrantFiled: July 17, 2001Date of Patent: November 5, 2002Assignee: 3-Dimensional Pharmaceuticals, Inc.Inventors: Aihua Wang, Bruce Edward Tomczuk, Tianbao Lu, Richard M. Soll, John Curtis Spurlino, Roger Francis Bone
-
Publication number: 20020161006Abstract: The present invention relates to compounds of the formula 1Type: ApplicationFiled: July 11, 2001Publication date: October 31, 2002Inventors: Mitsuhiro Kawamura, Makoto Kawai, Yuji Shishido, Tomoki Kato, Yasuhiro Katsu, Takafumi Ikeda, Noriaki Murase
-
Patent number: 6472399Abstract: Aminoguanidine and alkoxyguanidine compounds are described, including compounds of the Formula VII: wherein X is O or NR9 and Het, R1, R7, R8, R12-R15, Ra, Rb, Rc, Z, and n are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin. Also described are methods for preparing such compounds. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin. The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier.Type: GrantFiled: December 12, 2001Date of Patent: October 29, 2002Assignee: 3-Dimensional Pharmaceuticals, Inc.Inventors: Tianbao Lu, Bruce E. Tomczuk, Thomas P. Markotan, Colleen Siedem
-
Publication number: 20020156075Abstract: This invention relates to compounds which have activity as 5-HT1A agonists and antagonists which may be useful for the treatment of anxiety, depression, cognitive deficits, and prostate cancer, having the formula 1Type: ApplicationFiled: March 27, 2002Publication date: October 24, 2002Applicant: Wyeth (formerly American Home Products Corporation)Inventors: Wayne E. Childers, Michael G. Kelly, Yvette L. Palmer, Edward J. Podlesny
-
Patent number: 6458790Abstract: Certain novel substituted piperidine compounds are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment and control of obesity, diabetes, and sexual dysfunction, including erectile dysfunction and female sexual dysfunction.Type: GrantFiled: March 20, 2001Date of Patent: October 1, 2002Assignee: Merck & Co., Inc.Inventors: Brenda L. Palucki, Khaled J. Barakat, Liangqin Guo, Yingjie Lai, Ravi P. Nargund, Min K. Park, Patrick G. Pollard, Iyassu K. Sebhat, Zhixiong Ye
-
Patent number: 6458952Abstract: The invention relates to substituted polycyclic aryl and heteroaryl uracil compounds useful as inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.Type: GrantFiled: May 18, 2000Date of Patent: October 1, 2002Assignee: Pharmacia CorporationInventors: Michael South, Darin E. Jones, Melvin L. Rueppel
-
Patent number: 6458950Abstract: A compound shown by the formula II, wherein Het is a mono- or polycyclic heterocyclic group comprising one or more hetero atoms selected from the group consisting of N, O and S which may be the same or different from each other; R1 is hydrogen, an optionally substituted lower alkyl or an optionally substituted lower alkenyl; A is an optionally substituted lower alkylene, an optionally substituted lower alkenylene or a single bond; B is an optionally substituted imino or a single bond; or A and B taken together may form a single bond; and D is a single bond or a group of the formula (a):Type: GrantFiled: August 3, 2000Date of Patent: October 1, 2002Assignee: Shionogi & Co., Ltd.Inventors: Yasuhiro Nishitani, Koji Ishikura
-
Publication number: 20020111340Abstract: Compounds of formula (I) 1Type: ApplicationFiled: November 16, 2001Publication date: August 15, 2002Inventors: Youssef Bennani, Ramin Faghih
-
Patent number: 6403583Abstract: This invention relates generally to inhibitors of trypsin-like serine protease enzymes, especially factor Xa or thrombin, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders.Type: GrantFiled: December 22, 1999Date of Patent: June 11, 2002Inventors: Patrick Y. S. Lam, Charles G. Clark, John M. Fevig, Robert A. Galemmo, Qi Han, Irina C. Jacobson, Renhau Li, Donald J. P. Pinto, Ruth R. Wexler
-
Publication number: 20020058809Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds.Type: ApplicationFiled: November 2, 2001Publication date: May 16, 2002Inventors: Michel Jose Emmanuel, Eugene R. Hickey, Weimin Liu, Denice Mary Spero, Sanxing Sun, David S. Thomson, Yancey David Ward, Erick Richard Roush Young
-
Patent number: 6362183Abstract: An aromatic sulfonyl alpha-hydroxy hydroxamic acid compound that, inter alia, inhibits matrix metalloprotease activity is disclosed, as is a treatment process that comprises administering a contemplated aromatic sulfonyl alpha-hydroxy hydroxamic acid compound in an MMP enzyme-inhibiting effective amount to a host having a condition associated with pathological matrix metalloprotease activity.Type: GrantFiled: June 4, 1999Date of Patent: March 26, 2002Assignee: G. D. Searle & CompanyInventors: John N. Freskos, Terri L. Boehm, Brent V. Mischke, Robert M. Heintz, Joseph J. McDonald, Gary A. DeCrescenzo, Susan C. Howard
-
Patent number: 6204263Abstract: Pyrazinone compounds are described, including compounds of the Formula I: wherein X is O, NR11 or CH═N, R3-R11, Ra, Rb, Rc, W, m, and n are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin. Compositions for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation are described.Type: GrantFiled: June 11, 1999Date of Patent: March 20, 2001Assignee: 3-Dimensional Pharmaceuticals, Inc.Inventors: Tianbao Lu, Bruce E. Tomczuk, Thomas P. Markotan
-
Patent number: 6194413Abstract: The present invention relates to novel compounds which have hemoregulatory activities and can be used to stimulate hematopoiesis and for the treatment of viral, fungal and bacterial infectious diseases.Type: GrantFiled: May 12, 1998Date of Patent: February 27, 2001Assignee: SmithKline Beecham CorporationInventors: Pradip Kumar Bhatnagar, Dirk Andries Heerding
-
Patent number: 6180627Abstract: Compounds of formula (I): Are antithrombotic agents, having utility in a variety of therapeutic areas including the prevention and/or treatment of deep vein thrombosis (DVT) after surgery, major medical illness, paralysis, malignancy, prolonged immobilisation trauma, application of lower limb plaster casts, or fractures of the lower limbs or pelvis; recurrent DVT; DVT during pregnancy when there is a previous history thereof; reocclusion following thrombolytic therapy; chronic arterial obstruction; peripheral vascular disease; acute myocardial infarction; unstable angina; atrial fibrillation; thrombotic stroke; transient ischaemic attacks; disseminated intravascular coagulation; coagulation in extra-corporeal circuits; occlusion of aterio-venous shunts and blood vessel grafts (including coronary artery by-pass grafts); and restenosis and occlusion following angioplasty.Type: GrantFiled: August 11, 1999Date of Patent: January 30, 2001Assignee: Pfizer Inc.Inventors: Julian Blagg, Alan Daniel Brown, Elisabeth Colette Louise Gautier, Julian Duncan Smith, Andrew Brian McElroy
-
Patent number: 6159980Abstract: Corticotropin releasing factor (CRF) antagonists of Formula (I) ##STR1## and their use in treating psychiatric disorders and neurological diseases including major depression, anxiety-related disorders, post-traumatic stress disorders, supranuclear palsy and eating disorders.Type: GrantFiled: September 15, 1997Date of Patent: December 12, 2000Assignee: Dupont Pharmaceuticals CompanyInventors: Argyrios Georgios Arvanitis, Richard E. Olson, Charles R. Arnold, III, William E. Frietze
-
Patent number: 6147078Abstract: Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: ##STR1## wherein ##STR2##Type: GrantFiled: May 19, 1999Date of Patent: November 14, 2000Assignee: Merck & Co., Inc.Inventors: Philip E. Sanderson, Matthew G. Stanton, Suresh K. Balani
-
Patent number: 6093717Abstract: Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: ##STR1## wherein Y.sup.1 and Y.sup.2 are independently selected from the group consisting ofhydrogen,C.sub.1-4 alkyl,C.sub.1-4 alkoxy,C.sub.Type: GrantFiled: May 26, 1999Date of Patent: July 25, 2000Assignee: Merck & Co., Inc.Inventors: Philip E. Sanderson, Adel M. Naylor-Olsen
-
Patent number: 6087359Abstract: A thioaryl sulfonamide hydroxamic acid compound that inter alia inhibits matrix metalloprotease activity is disclosed as are a treatment process that comprises administering a contemplated thioaryl sulfonamide hydroxamic acid compound in a MMP enzyme-inhibiting effective amount to a host having a condition associated with pathological matrix metalloprotease activity.Type: GrantFiled: September 10, 1999Date of Patent: July 11, 2000Inventors: Daniel P. Getman, Daniel P. Becker, Thomas E. Barta, Clara I. Villamil, Susan L. Hockerman, Louis J. Bedell, Hui Li, John N. Freskos, Robert M. Heintz, Joseph J. McDonald, Gary A. DeCrescenzo
-
Patent number: 6060475Abstract: The invention concerns pharmaceutically useful compounds of the formula I, in which A.sup.1, A.sup.2, A.sup.3, A.sup.4, B.sup.1, m, Ar, W, X, Y, Z and R.sup.1 have any of the meanings defined herein, and their pharmaceutically acceptable salts, and pharmaceutical compositions containing them. The novel compounds possess endothelin receptor antagonist activity and are useful, for example, in the treatment of diseases or medical conditions in which elevated or abnormal levels of endothelin play a significant causative role. The invention further concerns processes for the manufacture of the novel compounds and the use of the compounds in medical treatment.Type: GrantFiled: December 14, 1998Date of Patent: May 9, 2000Assignee: Zeneca LimitedInventors: Robert Hugh Bradbury, Roger John Butlin, Roger James
-
Patent number: 5981537Abstract: The subject invention relates to pyrimidine-thioalkyl and alkylether compounds of Formula (I) and pyrimidine-thioalkyl and alkylethers of Formula (IA), namely the compounds of Formula (I) where R.sup.4 is selected from the group consisting of --H or --NR.sub.15 R.sub.16 where R.sub.15 is --H and R.sub.16 is --H, C.sub.1 -C.sub.6 alkyl, --NH.sub.2 or R.sub.15 and R.sub.16 taken together with the --N form 1-pyrrolidino, 1-morpholino or 1-piperidino; and R.sub.6 is selected from the group consisting of --H, or halo (preferably --Cl); with the overall proviso that R.sub.4 and R.sub.6 are not both --H. The compounds of Formula (IA) are useful in the treatment of individuals who are HIV positive.Type: GrantFiled: May 9, 1996Date of Patent: November 9, 1999Assignee: Pharmacia & Upjohn CompanyInventors: Richard A. Nugent, Stephen T. Schlachter, Michael J. Murphy, Joel Morris, Richard C. Thomas, Donn G. Wishka, Fritz Reusser, Gary J. Cleek, Irene W. Althaus
-
Patent number: 5972976Abstract: The invention relates to an aminostilbazole derivative of the following formula or a hydrate thereof, and a salt thereof. ##STR1## wherein R.sup.1 and R.sup.2 each represents hydrogen etc.; R.sup.3, R.sup.4, R.sup.13, and R.sup.14 each represents hydrogen, C.sub.1-3 acyl, halogen, hydroxy etc.; R.sup.5 represents hydrogen or hydroxy-substituted C.sub.1-3 alkyl etc.; R.sup.6 represents benzenesulfonyl substituted by C.sub.1-3 alkoxy etc.; ring Y represents phenyl etc.; ring Z represents 4-pyridyl, its oxide etc. The compound is useful or the treatment of various malignant tumors.Type: GrantFiled: October 2, 1996Date of Patent: October 26, 1999Assignee: Nippon Shinyaku Company, LimitedInventors: Hiroyoshi Hidaka, Akira Matsuura, Masato Matsuda
-
Patent number: 5939359Abstract: Substituted pyrazine derivatives of the general formula I ##STR1## where X is an oxygen or sulfur atom or a sulfoxyl or sulfonyl group;n is 0, 1 or 2;Z is a group ##STR2## where Y is oxygen or sulfur, R.sup.6 is hydrogen, alkyl, alkoxy, halogen or haloalkyl and p is 0 or 1;and R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 have the meanings stated in claim 1,and agriculturally useful salts of the compounds I are useful in herbicides.Type: GrantFiled: March 20, 1997Date of Patent: August 17, 1999Assignee: BASF AktiengesellschaftInventors: Stefan Engel, Christoph Nubling, Uwe Kardorff, Jurgen Kast, Wolfgang von Deyn, Peter Plath, Helmut Walter, Karl-Otto Westphalen, Matthias Gerber
-
Patent number: 5932606Abstract: A compound which inhibits human thrombin and where has the structure and pharmaceutically acceptable salts thereof, wherein such as ##STR1## which are useful for inhibiting formation of blood platelet aggregates in blood in a mammal.Type: GrantFiled: March 20, 1998Date of Patent: August 3, 1999Assignee: Merck & Co., Inc.Inventors: Richard C. A. Isaacs, Adel M. Naylor-Olsen, Bruce D. Dorsey, Christina L. Newton
-
Patent number: 5892046Abstract: The present invention relates to trifluoromethylpyridone-based methine and azamethine dyes of the formula I ##STR1## a process for their thermal transfer, a process for dyeing or printing synthetic materials and their use.Type: GrantFiled: April 24, 1997Date of Patent: April 6, 1999Assignee: BASF AktiengesellschaftInventors: Clemens Grund, Helmut Reichelt, Andreas Johann Schmidt, Stefan Beckmann
-
Patent number: 5889035Abstract: Heteroarylpiperidines, pyrrolidines, and piperazines are useful as antipsychotic and analgesic agents. The compounds are especially useful for treating psychoses by administering to a mammal a psychoses-treating effective amount of one of the compounds. Depot derivatives of the compounds are useful for providing long acting effects of the compounds. The compounds are also useful as analgesics by administering a pain-relieving effective amount of one of the compounds to a mammal.Type: GrantFiled: June 6, 1995Date of Patent: March 30, 1999Assignee: Hoechst Marion Roussel, Inc.Inventors: Joseph T. Strupczewski, Grover C. Helsley, Edward J. Glamkowski, Yulin Chiang, Kenneth J. Bordeau
-
Patent number: 5880125Abstract: The present invention is directed to certain novel compounds identified as 4-spiroindoline piperidines of the general structural formula: ##STR1## wherein R.sup.1, R.sup.1a, R.sup.2a, R.sup.3a, R.sup.3b, R.sup.4, R.sup.5, R.sup.8, and A are as defined herein. These compounds promote the release of growth hormone in humans and animals. This property can be utilized to promote the growth of food animals to render the production of edible meat products more efficient, and in humans, to treat physiological or medical conditions characterized by a deficiency in growth hormone secretion, such as short stature in growth hormone deficient children, and to treat medical conditions which are improved by the anabolic effects of growth hormone. Growth hormone releasing compositions containing these compounds as the active ingredient thereof are also disclosed.Type: GrantFiled: March 18, 1997Date of Patent: March 9, 1999Assignee: Merck & Co., Inc.Inventor: Ravi Nargund
-
Patent number: 5866568Abstract: The invention concerns pharmaceutically useful compounds of the formula I, in which A.sup.1, A.sup.2, A.sup.3, A.sup.4, B.sup.1, m, Ar, W, X, Y, Z and R.sup.1 have any of the meanings defined herein, and their pharmaceutically acceptable salts, and pharmaceutical compositions containing them. The novel compounds possess endothelin receptor antagonist activity and are useful, for example, in the treatment of diseases or medical conditions in which elevated or abnormal levels of endothelin play a significant causative role. The invention further concerns processes for the manufacture of the novel compounds and the use of the compounds in medical treatment.Type: GrantFiled: June 4, 1996Date of Patent: February 2, 1999Assignee: Zeneca LimitedInventors: Robert Hugh Bradbury, Roger John Butlin, Roger James
-
Patent number: 5866573Abstract: Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: ##STR1## for example: ##STR2##Type: GrantFiled: April 21, 1997Date of Patent: February 2, 1999Assignee: Merck & Co., Inc.Inventors: Philip E.. Sanderson, Terry A.. Lyle, Bruce D. Dorsey, Richard J. Varsolona
-
Patent number: 5849666Abstract: N-substituted hydrazinophenylsulfonylureas, processes for their preparation and their use as herbicides and plant growth regulatorsCompounds of the formula (I) or salts thereof ##STR1## in which R.sup.1 to R.sup.6, W, Q, X, Y and Z are defined as in formula (I) as claimed in claim 1, are suitable as herbicides and plant growth regulators.The compounds (I) are prepared by processes analogous to known processes (cf.Type: GrantFiled: November 22, 1995Date of Patent: December 15, 1998Assignee: Hoechst Schering Agrevo GmbHInventors: Heinz Kehne, Lothar Willms, Klaus Bauer, Hermann Bieringer, Christopher Rosinger
-
Patent number: 5849732Abstract: Disclosed are a phenol compound represented by the formula (1): ##STR1## wherein R.sup.0 represents H, alkyl or alkyloxy; R.sup.1 represents alkyl; R.sup.2 represents alkyl or alkyloxy; OR.sup.3 represents OH; R.sup.4 represents H, lower alkyl or acyl, each of the above substituents may be substituted; W represents O, S or NR.sup.7 ; where R.sup.7 represents H, alkyl, aryl, OH or alkyloxy, a group of the formula (2): ##STR2## represents an amino which may be mono- or di-substituted or heterocyclic group containing N atom,or a pharmaceutically acceptable salt thereof, and a process for preparing the same.Type: GrantFiled: February 14, 1997Date of Patent: December 15, 1998Assignee: Tanabe Seiyaku Co., Ltd.Inventors: Toshikazu Suzuki, Hiroshi Ohmizu, Yoshimasa Hashimura, Hitoshi Kubota, Keiko Tanaka